ATE360004T1 - Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften - Google Patents

Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften

Info

Publication number: ATE360004T1
Authority: AT; Austria
Prior art keywords: sub; sup; alkyl; heteroaryl; halogen
Prior art date: 2001-11-28

Application number

AT02779772T

Other languages

English (en)

Inventor

Michela Bettati

Mark Stuart Chambers

Alexander Charles Humphries

Philip Irbm Jones

Richard Thomas Lewis

Robert James Maxey

Helen Jane Szekeres

Martin Richard Teall

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-28

Filing date

2002-11-27

Publication date

2007-05-15

2002-11-27 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE360004T1 publication Critical patent/ATE360004T1/de

Links

239000003446 ligand Substances 0.000 title abstract 2
230000001149 cognitive effect Effects 0.000 title 1
150000005232 imidazopyridines Chemical class 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 6
229910052736 halogen Inorganic materials 0.000 abstract 5
150000002367 halogens Chemical class 0.000 abstract 5
125000001072 heteroaryl group Chemical group 0.000 abstract 5
125000000623 heterocyclic group Chemical group 0.000 abstract 3
239000004215 Carbon black (E152) Substances 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229930195733 hydrocarbon Natural products 0.000 abstract 2
150000002430 hydrocarbons Chemical class 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
102000004300 GABA-A Receptors Human genes 0.000 abstract 1
108090000839 GABA-A Receptors Proteins 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
230000019771 cognition Effects 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cosmetics (AREA)

AT02779772T 2001-11-28 2002-11-27 Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften ATE360004T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0128499.1A GB0128499D0 (en)	2001-11-28	2001-11-28	Therapeutic agents

Publications (1)

Publication Number	Publication Date
ATE360004T1 true ATE360004T1 (de)	2007-05-15

Family

ID=9926615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02779772T ATE360004T1 (de)	2001-11-28	2002-11-27	Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften

Country Status (10)

Country	Link
US (1)	US20060040940A1 (de)
EP (1)	EP1451161B1 (de)
JP (1)	JP2005518369A (de)
AT (1)	ATE360004T1 (de)
AU (1)	AU2002343110B2 (de)
CA (1)	CA2468893A1 (de)
DE (1)	DE60219672T2 (de)
ES (1)	ES2284941T3 (de)
GB (1)	GB0128499D0 (de)
WO (1)	WO2003048132A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1880998A1 (de) *	2003-07-25	2008-01-23	Neurogen Corporation	Imidazo-Pyrimide und Triazolo-Pyrimide: Benzodiazepin-Rezeptorliganden
BRPI0412908A (pt) *	2003-07-25	2006-09-26	Neurogen Corp	composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para o tratamento de ansiedade, depressão, um distúrbio do sono, distúrbio de déficit de atenção ou demência de alzheimer, para potenciar um efeito terapêutico de um agente do cns, para melhorar a memória de curta duração em um paciente, para alterar a atividade de transdução de sinal de receptor gabaa, e para determinar a presença ou ausência de receptor gabaa em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal
ZA200600037B (en) *	2003-07-25	2007-04-25	Neurogen Corp	Imidazo-pyrimidines and triazolo-pyrimidines: Benzodiazepine receptor ligands
US7329662B2 (en)	2003-10-03	2008-02-12	Hoffmann-La Roche Inc.	Pyrazolo-pyridine
GB0412769D0 (en)	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
WO2006099972A1 (en)	2005-03-23	2006-09-28	F. Hoffmann-La Roche Ag	Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
JP5048675B2 (ja)	2005-09-27	2012-10-17	エフ．ホフマン−ラロシュアーゲー	ｍＧｌｕＲ２アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
WO2008027812A2 (en) *	2006-08-28	2008-03-06	Forest Laboratories Holdings Limited	Imidazopyridine and imidazopyrimidine derivatives
HRP20150642T1 (hr)	2006-12-22	2015-08-14	Astex Therapeutics Limited	BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8513276B2 (en)	2006-12-22	2013-08-20	Astex Therapeutics Limited	Imidazo[1,2-a]pyridine compounds for use in treating cancer
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
AR068877A1 (es) *	2007-10-17	2009-12-09	Novartis Ag	Derivados heterociclicos de imidazol
EP2231660A1 (de) *	2007-12-21	2010-09-29	Wyeth LLC	Imidazo [1,2-a] pyridinverbindungen
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
US8222246B2 (en) *	2009-04-02	2012-07-17	Hoffmann-La Roche Inc.	Substituted isoxazoles
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
US8785435B2 (en)	2011-10-20	2014-07-22	Hoffmann-La Roche Inc.	Solid forms
US20150374705A1 (en)	2012-02-14	2015-12-31	Shanghai Institues for Biological Sciences	Substances for treatment or relief of pain
AP2015008718A0 (en)	2013-03-15	2015-09-30	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (de)	2013-03-15	2024-08-28	Global Blood Therapeutics, Inc.	Verbindungen und verwendungen davon zur modulation von hämoglobin
GB201321732D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
GB201321736D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
ES2860648T5 (es)	2014-02-07	2024-11-27	Global Blood Therapeutics Inc	Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
US11020382B2 (en)	2015-12-04	2021-06-01	Global Blood Therapeutics, Inc.	Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
KR102740831B1 (ko)	2017-11-14	2024-12-11	칠드런'즈 메디컬 센터 코포레이션	신규 이미다조피리미딘 화합물 및 그의 용도
EP3710007A4 (de) *	2017-11-14	2021-12-15	Children's Medical Center Corporation	Verwendung von imidazopyrimidin zur modulation der menschlichen immunantwort
CN116234549B (zh)	2020-08-05	2025-11-25	总医院公司	盐诱导激酶抑制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9503601D0 (en) *	1995-02-23	1995-04-12	Merck Sharp & Dohme	Method of treatment and method of manufacture of medicament
WO1998004560A1 (en) *	1996-07-25	1998-02-05	Merck Sharp & Dohme Limited	SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE
KR20000029548A (ko) *	1996-07-25	2000-05-25	더블유. 지. 콜	가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체
CA2288789C (en) *	1997-05-08	2009-07-21	Merck Sharp & Dohme Limited	Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
IL137117A0 (en) *	1998-02-25	2001-06-14	Merck Sharp & Dohme	Substituted 1,2,4-triazolo [3,4-a] pyridazine
GB9824897D0 (en) *	1998-11-12	1999-01-06	Merck Sharp & Dohme	Therapeutic compounds
GB9927687D0 (en) *	1999-11-23	2000-01-19	Merck Sharp & Dohme	Therapeutic agents
US6355638B1 (en) *	1999-11-25	2002-03-12	Merck Sharp & Dohme Ltd.	Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition
EP1294723A1 (de) *	2000-05-24	2003-03-26	MERCK SHARP & DOHME LTD.	3-phenyl-imidazo-pyrimidin derivate als liganden für gaba rezeptoren
GB0017518D0 (en) *	2000-07-17	2000-08-30	Merck Sharp & Dohme	Therapeutic agents
GB0017543D0 (en) *	2000-07-17	2000-09-06	Merck Sharp & Dohme	Therapeutic agents
CA2427779A1 (en) *	2000-11-10	2002-05-16	Merck Sharp & Dohme Limited	Imidazo-triazine derivatives as ligands for gaba receptors
GB0117277D0 (en) *	2001-07-16	2001-09-05	Merck Sharp & Dohme	Therapeutic agents
TWI248936B (en) *	2001-03-21	2006-02-11	Merck Sharp & Dohme	Imidazo-pyrimidine derivatives as ligands for GABA receptors
GB0125086D0 (en) *	2001-10-18	2001-12-12	Merck Sharp & Dohme	Novel compounds
GB0225501D0 (en) *	2002-11-01	2002-12-11	Merck Sharp & Dohme	Therapeutic agents
US7485640B2 (en) *	2002-11-06	2009-02-03	Merck Sharp & Dohme Limited	Imidazopyrazinones as GABA-A receptor anxiolytics
US6967255B2 (en) *	2004-02-06	2005-11-22	Industrial Technology Research Institute	Phenanthrene compounds

2001
- 2001-11-28 GB GBGB0128499.1A patent/GB0128499D0/en not_active Ceased
2002
- 2002-11-27 US US10/497,002 patent/US20060040940A1/en not_active Abandoned
- 2002-11-27 AU AU2002343110A patent/AU2002343110B2/en not_active Ceased
- 2002-11-27 DE DE60219672T patent/DE60219672T2/de not_active Expired - Lifetime
- 2002-11-27 AT AT02779772T patent/ATE360004T1/de not_active IP Right Cessation
- 2002-11-27 JP JP2003549324A patent/JP2005518369A/ja active Pending
- 2002-11-27 CA CA002468893A patent/CA2468893A1/en not_active Abandoned
- 2002-11-27 WO PCT/GB2002/005337 patent/WO2003048132A1/en not_active Ceased
- 2002-11-27 EP EP02779772A patent/EP1451161B1/de not_active Expired - Lifetime
- 2002-11-27 ES ES02779772T patent/ES2284941T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20060040940A1 (en)	2006-02-23
WO2003048132A1 (en)	2003-06-12
ES2284941T3 (es)	2007-11-16
AU2002343110A1 (en)	2003-06-17
EP1451161A1 (de)	2004-09-01
EP1451161B1 (de)	2007-04-18
DE60219672D1 (de)	2007-05-31
GB0128499D0 (en)	2002-01-23
DE60219672T2 (de)	2007-12-27
CA2468893A1 (en)	2003-06-12
AU2002343110B2 (en)	2008-10-30
JP2005518369A (ja)	2005-06-23

Legal Events

Date	Code	Title	Description
2007-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE360004T1 (de)	2007-05-15	Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
RU2309951C2 (ru)	2007-11-10	Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение
AR037682A1 (es)	2004-12-01	Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
EA200201179A1 (ru)	2003-04-24	Производные 2-аминокарбонил-9h-пурина
DK1261602T3 (da)	2004-08-30	Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
BR0314392A (pt)	2005-07-12	Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
HK1041257A1 (zh)	2002-07-05	作為nk-3受體拮抗劑的喹啉-4-酰胺衍生物
BG107171A (bg)	2003-07-31	Производни на пурин
AR035935A1 (es)	2004-07-28	El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprende
EA200700099A1 (ru)	2007-08-31	Производные пиридина
RU2008112691A (ru)	2009-10-10	Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
EA200000700A3 (ru)	2001-04-23	НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ
DE602004012758D1 (de)	2008-05-08	Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
BRPI0506848A (pt)	2007-06-12	composto,uso do mesmo, formulação farmacêutica e produto farmacêutico
ATE530182T1 (de)	2011-11-15	Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
TR200000727T2 (tr)	2000-09-21	5HT geri alım inhibitörü ve h5-HT1B antagonistinin bir bileşimi.
WO2005040345A3 (en)	2005-08-18	4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
EA200401455A1 (ru)	2005-06-30	Производные бензоксазина в качестве модуляторов 5-htи их применение
DK1320526T3 (da)	2010-10-18	Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser
DE60014394D1 (de)	2004-11-04	Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
MX2012008147A (es)	2012-08-03	Derivados de pirrazolopiridina.
AR059490A1 (es)	2008-04-09	Cmpuestos antivirales heterociclicos
TW200510320A (en)	2005-03-16	Aminoquinoline derivatives and their use as adenosine A3 ligands
EA200100090A2 (ru)	2001-08-27	Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
AR037611A1 (es)	2004-11-17	Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden